Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) face significant survival disparities and ...

An international clinical trial shows an innovative CAR-T cell immunotherapy is promising against aggressive T cell cancers and has manageable side effects.

Outcome of Acute Promyelocytic Leukemia (APL) in Children and Adolescents: An Analysis in Two Consecutive Trials of the European APL Group The prognosis of acute- and lymphoma-type adult T-cell ...

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, ...

Allogeneic CAR-T cell therapy is produced using CRISPR gene editing from cells donated by healthy individuals.

The results apply to 93 adult patients with ... of standard of care CAR-T-cell treatment for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia in Sweden, Leukemia (2025).

Researchers sought to determine whether the ALL-Hematotox would be able to predict hematotoxicity for patients with B-ALL who are at risk of severe hematotoxicity following CAR-T therapy.

I’ve lived with large granular lymphocytic leukemia for 16 years and have learned to spend my energy wisely, embrace ...

Researchers sought to determine whether venetoclax plus low-intensity chemotherapy would be effective in adult patients with ALL.

An international clinical trial led by WashU Medicine researchers shows an innovative CAR-T cell immunotherapy is promising ...

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results ...

adult T-cell leukemia–lymphoma (ATL) is first divided into two groups: indolent (i.e., smoldering or chronic type) or aggressive (i.e., acute or lymphoma type). The prognosis of indolent ATL is ...